Search

Your search keyword '"Feres F"' showing total 310 results
Start Over Author "Feres F"
310 results on '"Feres F"'

3. Sub-diffractional cavity modes of terahertz hyperbolic phonon polaritons in tin oxide

Author

Feres, F. H., Mayer, R. A., Wehmeier, L., Maia, F. C. B., Viana, E. R., Malachias, A., Bechtel, H. A., Klopf, J. M., Eng, L. M., Kehr, S. C., González, J. C., Freitas, R. O., and Barcelos, I. D.

Subjects
near-field, Physics::Optics, s-SNOM, THz, phonon polariton
Abstract

Hyperbolic phonon polaritons have recently attracted considerable attention in nanophotonics mostly due to their intrinsic strong electromagnetic field confinement, ultraslow polariton group velocities, and long lifetimes. Here we introduce tin oxide (SnO2) nanobelts as a photonic platform for the transport of surface and volume phonon polaritons in the mid- to far-infrared frequency range. This report brings a comprehensive description of the polaritonic properties of SnO2 as a nanometer-sized dielectric and also as an engineered material in the form of a waveguide. By combining accelerator-based IR-THz sources (synchrotron and free-electron laser) with s-SNOM, we employed nanoscale far-infrared hyperspectral-imaging to uncover a Fabry–Perot cavity mechanism in SnO2 nanobelts via direct detection of phonon-polariton standing waves. Our experimental findings are accurately supported by notable convergence between theory and numerical simulations. Thus, the SnO2 is confirmed as a natural hyperbolic material with unique photonic properties essential for future applications involving subdiffractional light traffic and detection in the farinfrared range.

Published
2021

4. Sub-diffractional cavity modes of terahertz hyperbolic phonon polaritons in tin oxide

Author

(0000-0001-9812-974X) Feres, F. H., Mayer, R. A., (0000-0001-8416-953X) Wehmeier, L., (0000-0002-4998-4624) Maia, F. C. B., Viana, E. R., Malachias, A., Bechtel, H. A., (0000-0002-3431-6666) Klopf, J. M., (0000-0002-2484-4158) Eng, L. M., Kehr, S. C., González, J. C., (0000-0002-3285-5447) Freitas, R. O., (0000-0002-5778-7161) Barcelos, I. D., (0000-0001-9812-974X) Feres, F. H., Mayer, R. A., (0000-0001-8416-953X) Wehmeier, L., (0000-0002-4998-4624) Maia, F. C. B., Viana, E. R., Malachias, A., Bechtel, H. A., (0000-0002-3431-6666) Klopf, J. M., (0000-0002-2484-4158) Eng, L. M., Kehr, S. C., González, J. C., (0000-0002-3285-5447) Freitas, R. O., and (0000-0002-5778-7161) Barcelos, I. D.

Abstract

Hyperbolic phonon polaritons have recently attracted considerable attention in nanophotonics mostly due to their intrinsic strong electromagnetic field confinement, ultraslow polariton group velocities, and long lifetimes. Here we introduce tin oxide (SnO2) nanobelts as a photonic platform for the transport of surface and volume phonon polaritons in the mid- to far-infrared frequency range. This report brings a comprehensive description of the polaritonic properties of SnO2 as a nanometer-sized dielectric and also as an engineered material in the form of a waveguide. By combining accelerator-based IR-THz sources (synchrotron and free-electron laser) with s-SNOM, we employed nanoscale far-infrared hyperspectral-imaging to uncover a Fabry–Perot cavity mechanism in SnO2 nanobelts via direct detection of phonon-polariton standing waves. Our experimental findings are accurately supported by notable convergence between theory and numerical simulations. Thus, the SnO2 is confirmed as a natural hyperbolic material with unique photonic properties essential for future applications involving subdiffractional light traffic and detection in the farinfrared range.

Published
2021

5. A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making

Author

Costa, F. (Francesco), Klaveren, D. (David) van, Colombo, A. (Antonio), Feres, F. (Fausto), Räber, L. (Lorenz), Pilgrim, T. (Thomas), Hong, M.-K. (Myeong-Ki), Kim, H.-S. (Hyo-Soo), Windecker, S.W. (Stephan), Steyerberg, E.W. (Ewout), Valgimigli, M. (Marco), Costa, F. (Francesco), Klaveren, D. (David) van, Colombo, A. (Antonio), Feres, F. (Fausto), Räber, L. (Lorenz), Pilgrim, T. (Thomas), Hong, M.-K. (Myeong-Ki), Kim, H.-S. (Hyo-Soo), Windecker, S.W. (Stephan), Steyerberg, E.W. (Ewout), and Valgimigli, M. (Marco)

Abstract

The originally-proposed PRECISE-DAPT score is a 5-item risk score supporting decision-making for dual antiplatelet therapy1 duration after PCI. It is unknown if a simplified version of the score based on 4 factors (age, hemoglobin, creatinine clearance, prior bleeding), and lacking white-blood cell count, retains potential to guide DAPT duration. The 4-item PRECISE-DAPT was used to categorize 10,081 patients who were randomized to short (3-6 months) or long (12-24 months) DAPT regimen according to high (HBR defined by PRECISE-DAPT ≥25 points) or non-high bleeding risk (PRECISE-DAPT<25) status. Long treatment duration was associated with higher bleeding rates in HBR (ARD +2.22% [95% CI +0.53 to +3.90]) but not in non-HBR patients (ARD +0.25% [−0.14 to +0.64]; pint = 0.026), and associated with lower ischemic risks in non-HBR (ARD −1.44% [95% CI −2.56 to −0.31]), but not in HBR patients (ARD +1.16% [−1.91 to +4.22]; pint = 0.11). Only non-HBR patients experienced lower net clinical adverse events (NACE) with longer DAPT (pint = 0.043). A 4-item simplified version of the PRECISE-DAPT score retains the potential to categorize patients who benefit from prolong

Published
2020
Full Text
View/download PDF

7. Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey

Author

Adamo, Marianna, Byrne, Robert A., Baumbach, Andreas, Haude, Michael, Windecker, Stephan, Valgimigli, Marco, Aaroe, J., Abdeltawab, A. A., Accardi, R., Addad, F., Agostoni, P., Alajab, A., Alcázar, E., Alhabil, B., Altug Cakmak, H., Amico, F., Amoroso, G., Anderson, R., Andò, G., Andreou, A. Y., Antoniadis, D., Aquilina, M., Aramberry, L., Auer, J., Auffret, V., Ausiello, A., Austin, D., Avram, A., Ayman, E., Babunashvili, V., Bagur, R., Bakotic, Z., Balducelli, M., Ballesteros, S. M., Baptista, S., Baranauskas, A., Barbeau, G., Bax, M., Benchimol, C., Berroth, R., Biasco, L., Bilal, A., Binias, K., Blanco Mata, R., Boccuzzi, G., Bolognese, L., Boskovic, S., Bourboulis, N., Briguori, C., Bunc, M., Buysschaert, I., Calabro’, P., Campo, G., Candiello, A., Caprotta, U. F., Cardenas, M., Carrilho-Ferreira, P., Carrizo, S., Caruso, M., Cassar, A., Cernigliaro, C., Chacko, G., Chamie, D., Clapp, B., Coceani, M., Colangelo, S., Colombo, A., Comeglio, M., Connaughton, M., Conway, D., Cortese, B., Cosgrave, J., Costa, F., Couvoussis, E., Crimi, G., Crook, R., Cruz-Alvarado, J. E., Curello, S., D’Ascenzo, F., D’Urbano, M., Dana, A., De Backer, O., De Carlo, M., De Cesare, N., De Iaco, G., De La Torre, H. J. M., De Oliveira Netoj, B., Devlin, G. P., Di Lorenzo, E., Díaz, A., Dina, C., Dorsel, T. H., Eberli, F. R., Echeverría, R., Eftychiou, C., Elguindy, A., Ercilla, J., Ernst, A., Esposito, G., Ettori, F., Eufracino, Null, Ezquerra Aguilera, W., Falcone, C., Falu, R. M., Feres, F., Ferlini, M., Fernández, G., Fernández-Rodríguez, D., Fileti, L., Fischetti, D., Florescu, N., Formigli, D., Fouladvand, F., Franco, N., Fresco, C., Frigoli, E., Furmaniuk, J., Gabaldo, K., Galli, M., Galli, S., Garbo, R., Garducci, S., Garg, S., Gavrielatos, G., Gensch, J., Giacchi, G., Giunio, L., Giustino, G., Goldberg, L., Goldsmit, R., Gommeaux, A., González Godínez, H., Gosselin, G., Govorov, A., Grimfjard, P., Gross, E., Grosz, C., Guagliumi, G., Hadad, W., Hadadi, L., Hansen, P. R., Harb, S., Hatrick, R., Hayrapetyan, H. G., Hernández-Enríquez, M., Ho Heo, J., Horvath, I. G., Huan Loh, P., Ibrahim, A. M., Ierna, S., Ilic, I., Imperadore, F., Ionescu-Silva, E., Jacksch, R., James, S., Janiak, B., Jensen, S. E., Jeroen, S., Jugessur, R. K., Kala, P., Kambis, M., Kanakakis, J., Karamasis, G., Karchevsky, D., Karpovskiy, A., Kayaert, P., Kedev, S., Kemala, E., Ketteler, T., Khan, S. Q., Kharlamov, A., Kiernan, T., Kiviniem, T., Koltowski, L., Koskinas, K. C., Kouloumpinis, A., Kraaijeveld, A. O., Krizanic, F., Krötz, B., Kuczmik, W., Kukreja, N., Kuksa, D., Yav, K., Kyriakos, D., Labrunie, A., Laine, M., Lapin, O., Larosa, C., Latib, A., Lattuca, B., Lauer, B., Lefèvre, T., Legrand, V., Lehto, P., Leiva-Pons, J. L., Leone, A. M., Lev, G., Lim, R., Limbruno, U., Linares Vicente, J. A., Lindsay, S., Linnartz, C., Liso, A., Lluberas, R., Locuratolo, N., Lokshyn, S., Lunde, K., Lupi, A., Magnavacchi, P., Maia, F., Mainar, V., Mancone, M., Manolios, M. G., Mansour, S., Mariano, E., Marques, K., Martins, H., Mckenzie, D., Meco, S., Meemook, K., Mehmed, K., Melikyan, A., Mellwig, K. P., Mendiz, O. A., Merkulov, E., Mesquita, H. G., Mezzapelle, G., Miloradovic, V., Mohamed, S., Mohammed, B., Mohammed, F., Mohammed, K., Mohanad, A., Morawiec, B., More, R., Moreno-Martínez, F. L., Mrevlje, B., Muhammad, F., Näveri, H., Nazzaro, M. S., Neary, P., Negus, B. H., Nelson Durval, F. G., Nick, H., Nilva, E., Oldroyd, K. G., Olivares Asencio, C., Omerovic, E., Ortiz, M. A., Ota, H., Otasevic, P., Otieno, H. A., Paizis, I., Papp, E., Pasquetto, G., Patsourakos, N. G., Peels, J., Pelliccia, F., Pennacchi, M., Penzo, C., Perez, P., Perkan, A., Petrou, E., Phipathananunth, W., Pierri, A., Pinheiro, L. F., Pipa, J. L., Piva, T., Polad, J., Porto, I., Poveda, J., Predescu, L., Prog, R., Puri, R., Raco, D. L., Ramazan, O., Ramazzotti, V., Rao, S. V., Raungaard, B., Reczuch, K., Rekik, S., Rhouati, A., Rigattieri, S., Rodríguez-Olivares, R., Roik, M., Romagnoli, E., Román, A. J., Routledge, H., Rubartelli, P., Rubboli, A., Ruiz-García, J., Russo, F., Ruzsa, Z., Ryding, A., Saad, Aly, Sabate, M., Sabouret, P., Sadowski, M., Saia, F., Sanchez Perez, I., Santoro, G. M., Sarenac, D., Saririan, M., Sarma, J., Schuetz, T., Sciahbasi, A., Sebastian, M., Sebik, R., Sesana, M., Hur, Seung-Ho, Sganzerla, P., Shalva, R., Sharma, S., Sheiban, I., Shein, K. K., Shiekh, I. A., Sinha, M., Slhessarenko, J., Smith, D., Smyth, D. W., Sönmez, K., Sood, N., Sourgounis, A., Srdanovic, I., Stables, R. H., Stefanini, G. G., Stewart, J., Stoyanov, N., Suliman, A. A., Suryadevara, R., Suwannasom, P., Tange Veien, K., Tauchert, S., Tebet, M., Testa, L., Thury, A., Tilsted, H. H., Tiroch, K., Torres, A., Tosi, P., Traboulsi, M., Trani, C., Tresoldi, S., Tsigkas, G., Tueller, D., Turri, M., Udovichenko, A. E., Uretsky, B., Van Der Harst, P., Van Houwelingen, K. G., Vandoni, P., Vandormael, M., Varbella, F., Venkitachalam, C. G., Vercellino, M., Vidal-Perez, R., Vigna, C., Vignali, L., Vogt, F., Voudris, V., Vranckx, P., Vrolix, M., Vydt, T., Webster, M., Wijns, W., Woody, W., Wykrzykowska, J., Yazdani, S., Yildiz, A., Yurlevich, D., Zauith, R., Zekanovic, D., Zhao, M., Zimarino, M., Zingarelli, A., Abdelsamad, A. Y., Abo Shaera, E. S., Afshar, M. S., Agatiello, C., Aguiar, P., Ahmad, A. M., Akin, I., Alameda, M., Alegría-Barrero, E., Alejos, R., Alkhashab, K., Alkutshan, R. S. A., Almorraweh, A., Altnji, I., Alvarez Iorio, C., Anchidin, O., Angel, J., Antonopoulos, A., Apshilava, G., Arana, C., Ashikaga, T., Assomull, R., Atef, S. Z., Azmus, A. D., Azzalini, L., Azzouz, A., Baglioni, P., Bampas, G., Basil, M. P., Baumbach, A., Besh, D., Bhushan Sharm, A., Bien Hsien, H., Bihui, L., Bing-Chen, L., Biryukov, S., Blatt, A., Bocchi, E., Boghdady, A., Bonarjee, V. V. S., Bosnjak, I., Bravo Baptista, S., Brinckman, S. L., Buchter, B., Burzotta, F., Cacucci, M., Cagliyan, C. E., Calabrò, P., Cernetti, C., Chávez Mizraym, R., Choo, W. S., Choudhury, R., Cicco, N., Cisneros Clavijo, P., Çitaku, H., Collet, J. P., Consuegra-Sánchez, L., Conte, M., Corral, J. M., Damonte, A., Dangoisse, V., Dastani, M., Della Rosa, F., Deora, S., Devadathan, S., Dharma, S., Di Giorgio, A., Diez, J. L., Dinesha, B., Duplančić, D., El Behwashi, M. F., Elghawaby, H., Elshahawy, O., Eskola, M. J., Etman, A., Eun Gyu, L., Fabiano, L., Facta, A., Fan, Y., Fang-Yang, H., Farag, E., Fathi, Y., Fazeli, N., Federico, P., Fereidoun, M. Z., Fernandez-Nofrerias, E., Flensted Lassen, J., Flessas, D., Fouad, H., Franco-Pelaez, J. A., Fu, Q., Furtado, R., Gadepalli, R., Gallino, R., Gasparetto, V., Gentiletti, A., Gholoobi, A., Ghosh, A. K., Gkizas, S., Golchha, S. K., Goncharov, A., Gössl, M., Götberg, M., Greco, F., Grundeken, M. J., Gupta, D., Gupta, S., Guray, U., Hahalis, G., Hakim Vista, J., Hamid, M. A., Hammoudeh, A., Hasan, A. R. I., Hatsumura, F. E., Heintzen, M. P., Helal, T., Hetherington, S., Hewarathna, U. I., Hioki, H., Hissein, F., Ho-Ping, Y., Homs, S., Huber, K., Ibarra, F. M., Ielasi, A., Ipek, E., Jambunathan, R., Jamshidi, P., Jarrad, I., Javier, W., Jensen, J., Jimenez-Quevedo, P., Kalpak, O., Kan, J., Kanaan, T., Kao, D. H. M., Karamfiloff, K., Karegren, A., Karjalainen, P. P., Kasabov, R., Katsimagklis, G. D., Kaul, U., Khan, A., Kiemeneij, E., Kiviniemi, T., Kleiban, A., Komiyama, N., Konteva, M., Koshy, G., Krepsky, A. M., Kuljit, S., Kulkarni, P., Kumar, V., Kuznetsov, I., Lai, G., Lateef, M. A., Lawand, S., Le Hong, T., Lettieri, C., Levy, G., Lindvall, P., Maitra, A., Makowski, M., Mamas, M. A., Mandal, S. C., Mangalanandan, P., Marin, R., Mashhadi, M., Matsukage, T., Meier, B., Milosavljevic, B., Miro, S. S., Mitov, A., Moeriel, M., Moguel, R., Mohanty, A., Montalescot, G., Mörsdorf, W., Moscato, F., Muniz, A., Muraglia, S., Myć, J., Nada, A., Nair, P., Namazi, M. H., Naraghipour, F., Nguyen, Q. N., Nicosia, A., Nikas, D., Ober, M., Ocaranza-Sánchez, R., Olivecrona, G., Pahlajani, D., Pandey, B. P., Parma, A., Parma, R., Patsilinakos, S. P., Pattam, J., Peddi, S., Perez, P. R., Peruga, J. Z., Pescoller, F., Petrov, I., Piatti, L., Pico-Aracil, F., Pina, J., Piroth, Z., Popa, V., Pourbehi, M. R., Pradhan, A. K., Prida, X. E., Purohit, B. V., Pyun, W. B., Quang Hung, D., Rada, I., Rafizadeh, O., Rahman, M. A., Rai, L., Ramsewak, A., Ravindran, R., Rodriguez De Leiras, O. S., Rodríguez Esteban, M., Roque Figueira, H., Saket, A., Sakhov, O., Saktheeswaran, M. K., Salachas, A., Sallam, A., Sampaolesi, A., Samy, A., Sanchis, J., Santaera, O., Santarelli, A., Santharaj, W. S., Sarango, B., Satheesh, S., Schmitz, T., Schühlen, H., Seewoosagur, R., Segev, A., Seisembekov, V., Semitko, S., Sengottuvelu, G., Sepulveda Varela, P., Sethi, A., Sharma, A., Sharma, R. K., Shi, Hy., Şimşek, M. A., Siqueira, B., Skalidis, E., Slawin, J., Sorokhtey, L., Spaulding, C., Srinivas, B., Srinivasan, M., Stakos, D., Stefanini, G., Stojkovic, S., Tacoy, G., Tawade, M., Tiecco, F., Tondi, S., Torresani, E. M., Tousek, P., Tran, T., Trantalis, G., Triantafyllou, K., Trivedi, R., Trivisonno, A., Tsui, K. L., Türkoğlu, C., Tzung-Dau, W., Ueno, H., Urban, U., Uretsky, B. F., Uscumlic, A., Venugopal, V., Verney, R., Vilar, J. V., Villacorta, V. G., Vishwanath, R., Vlachojannis, G. J., Vlachojannis, M., Vlad, V., Von Birgelen, C., Vukcevic, V., Wahab, A., Waksman, R., Wei-Wen, L., Weisz, G., Whittaker, A., Yadav, A., Yokoi, Y., Zacharoulis, A., Zahran, M., Zamani, J., Ziakas, A., Zimmermann, J. P., Adamo, M., Byrne, R. A., Baumbach, A., Haude, M., Windecker, S., Valgimigli, M., Aaroe, J., Abdeltawab, A. A., Accardi, R., Addad, F., Agostoni, P., Alajab, A., Alcazar, E., Alhabil, B., Altug Cakmak, H., Amico, F., Amoroso, G., Anderson, R., Ando, G., Andreou, A. Y., Antoniadis, D., Aquilina, M., Aramberry, L., Auer, J., Auffret, V., Ausiello, A., Austin, D., Avram, A., Ayman, E., Babunashvili, V., Bagur, R., Bakotic, Z., Balducelli, M., Ballesteros, S. M., Baptista, S., Baranauskas, A., Barbeau, G., Bax, M., Benchimol, C., Berroth, R., Biasco, L., Bilal, A., Binias, K., Blanco Mata, R., Boccuzzi, G., Bolognese, L., Boskovic, S., Bourboulis, N., Briguori, C., Bunc, M., Buysschaert, I., Calabro', P., Campo, G., Candiello, A., Caprotta, U. F., Cardenas, M., Carrilho-Ferreira, P., Carrizo, S., Caruso, M., Cassar, A., Cernigliaro, C., Chacko, G., Chamie, D., Clapp, B., Coceani, M., Colangelo, S., Colombo, A., Comeglio, M., Connaughton, M., Conway, D., Cortese, B., Cosgrave, J., Costa, F., Couvoussis, E., Crimi, G., Crook, R., Cruz-Alvarado, J. E., Curello, S., D'Ascenzo, F., D'Urbano, M., Dana, A., De Backer, O., De Carlo, M., De Cesare, N., De Iaco, G., De La Torre, H. J. M., De Oliveira Netoj, B., Devlin, G. P., Di Lorenzo, E., Diaz, A., Dina, C., Dorsel, T. H., Eberli, F. R., Echeverria, R., Eftychiou, C., Elguindy, A., Ercilla, J., Ernst, A., Esposito, G., Ettori, F., Eufracino, Ezquerra Aguilera, W., Falcone, C., Falu, R. M., Feres, F., Ferlini, M., Fernandez, G., Fernandez-Rodriguez, D., Fileti, L., Fischetti, D., Florescu, N., Formigli, D., Fouladvand, F., Franco, N., Fresco, C., Frigoli, E., Furmaniuk, J., Gabaldo, K., Galli, M., Galli, S., Garbo, R., Garducci, S., Garg, S., Gavrielatos, G., Gensch, J., Giacchi, G., Giunio, L., Giustino, G., Goldberg, L., Goldsmit, R., Gommeaux, A., Gosselin, G., Govorov, A., Gonzalez Godinez, H., Gross, E., Grosz, C., Guagliumi, G., Hadad, W., Hadadi, L., Hansen, P. R., Harb, S., Hatrick, R., Hayrapetyan, H. G., Hernandez-Enriquez, M., Ho Heo, J., Horvath, I. G., Huan Loh, P., Ibrahim, A. M., Ierna, S., Ilic, I., Imperadore, F., Ionescu-Silva, E., Jacksch, R., James, S., Janiak, B., Jensen, S. E., Jeroen, S., Jugessur, R. K., Kala, P., Kambis, M., Kanakakis, J., Karamasis, G., Karchevsky, D., Karpovskiy, A., Kayaert, P., Kedev, S., Kemala, E., Ketteler, T., Khan, S. Q., Kharlamov, A., Kiernan, T., Kiviniem, T., Koltowski, L., Koskinas, K. C., Kouloumpinis, A., Kraaijeveld, A. O., Krizanic, F., Krotz, B., Kuczmik, W., Kukreja, N., Kuksa, D., Yav, K., Kyriakos, D., Labrunie, A., Laine, M., Lapin, O., Larosa, C., Latib, A., Lattuca, B., Lauer, B., Lefevre, T., Legrand, V., Lehto, P., Leiva-Pons, J. L., Leone, A. M., Lev, G., Lim, R., Limbruno, U., Linares Vicente, J. A., Lindsay, S., Linnartz, C., Liso, A., Lluberas, R., Locuratolo, N., Lokshyn, S., Lunde, K., Lupi, A., Magnavacchi, P., Maia, F., Mainar, V., Mancone, M., Manolios, M. G., Mansour, S., Mariano, E., Marques, K., Martins, H., Mckenzie, D., Meco, S., Meemook, K., Mehmed, K., Melikyan, A., Mellwig, K. P., Mendiz, O. A., Merkulov, E., Mesquita, H. G., Mezzapelle, G., Miloradovic, V., Mohamed, S., Mohammed, B., Mohammed, F., Mohammed, K., Mohanad, A., Morawiec, B., More, R., Moreno-Martinez, F. L., Mrevlje, B., Muhammad, F., Naveri, H., Nazzaro, M. S., Neary, P., Negus, B. H., Nelson Durval, F. G., Nick, H., Nilva, E., Oldroyd, K. G., Olivares Asencio, C., Omerovic, E., Ortiz, M. A., Ota, H., Otasevic, P., Otieno, H. A., Paizis, I., Papp, E., Pasquetto, G., Patsourakos, N. G., Peels, J., Pelliccia, F., Pennacchi, M., Penzo, C., Perez, P., Perkan, A., Petrou, E., Phipathananunth, W., Pierri, A., Pinheiro, L. F., Pipa, J. L., Piva, T., Polad, J., Porto, I., Poveda, J., Predescu, L., Prog, R., Puri, R., Raco, D. L., Ramazan, O., Ramazzotti, V., Rao, S. V., Raungaard, B., Reczuch, K., Rekik, S., Rhouati, A., Rigattieri, S., Rodriguez-Olivares, R., Roik, M., Romagnoli, E., Roman, A. J., Routledge, H., Rubartelli, P., Rubboli, A., Ruiz-Garcia, J., Russo, F., Ruzsa, Z., Ryding, A., Saad, A., Sabate, M., Sabouret, P., Sadowski, M., Saia, F., Sanchez Perez, I., Santoro, G. M., Sarenac, D., Saririan, M., Sarma, J., Schuetz, T., Sciahbasi, A., Sebastian, M., Sebik, R., Sesana, M., Hur, S. -H., Sganzerla, P., Shalva, R., Sharma, S., Sheiban, I., Shein, K. K., Shiekh, I. A., Sinha, M., Slhessarenko, J., Smith, D., Smyth, D. W., Sonmez, K., Sood, N., Sourgounis, A., Srdanovic, I., Stables, R. H., Stefanini, G. G., Stewart, J., Stoyanov, N., Suliman, A. A., Suryadevara, R., Suwannasom, P., Tange Veien, K., Tauchert, S., Tebet, M., Testa, L., Thury, A., Tilsted, H. H., Tiroch, K., Torres, A., Tosi, P., Traboulsi, M., Trani, C., Tresoldi, S., Tsigkas, G., Tueller, D., Turri, M., Udovichenko, A. E., Uretsky, B., Van Der Harst, P., Van Houwelingen, K. G., Vandoni, P., Vandormael, M., Varbella, F., Venkitachalam, C. G., Vercellino, M., Vidal-Perez, R., Vigna, C., Vignali, L., Vogt, F., Voudris, V., Vranckx, P., Vrolix, M., Vydt, T., Webster, M., Wijns, W., Woody, W., Wykrzykowska, J., Yazdani, S., Yildiz, A., Yurlevich, D., Zauith, R., Zekanovic, D., Zhao, M., Zimarino, M., Zingarelli, A., Abdelsamad, A. Y., Abo Shaera, E. S., Afshar, M. S., Agatiello, C., Aguiar, P., Ahmad, A. M., Akin, I., Alameda, M., Alegria-Barrero, E., Alejos, R., Alkhashab, K., Alkutshan, R. S. A., Almorraweh, A., Altnji, I., Alvarez Iorio, C., Anchidin, O., Angel, J., Antonopoulos, A., Apshilava, G., Arana, C., Ashikaga, T., Assomull, R., Atef, S. Z., Azmus, A. D., Azzalini, L., Azzouz, A., Baglioni, P., Bampas, G., Basil, M. P., Besh, D., Bhushan Sharm, A., Bien Hsien, H., Bihui, L., Bing-Chen, L., Biryukov, S., Blatt, A., Bocchi, E., Boghdady, A., Bonarjee, V. V. S., Bosnjak, I., Bravo Baptista, S., Brinckman, S. L., Buchter, B., Burzotta, F., Cacucci, M., Cagliyan, C. E., Cernetti, C., Chavez Mizraym, R., Choo, W. S., Choudhury, R., Cicco, N., Cisneros Clavijo, P., Citaku, H., Collet, J. P., Consuegra-Sanchez, L., Conte, M., Corral, J. M., Damonte, A., Dangoisse, V., Dastani, M., Della Rosa, F., Deora, S., Devadathan, S., Dharma, S., Di Giorgio, A., Diez, J. L., Dinesha, B., Duplancic, D., El Behwashi, M. F., Elghawaby, H., Elshahawy, O., Eskola, M. J., Etman, A., Eun Gyu, L., Fabiano, L., Facta, A., Fan, Y., Fang-Yang, H., Farag, E., Fathi, Y., Fazeli, N., Federico, P., Fereidoun, M. Z., Fernandez-Nofrerias, E., Flensted Lassen, J., Flessas, D., Fouad, H., Franco-Pelaez, J. A., Fu, Q., Furtado, R., Gadepalli, R., Gallino, R., Gasparetto, V., Gentiletti, A., Gholoobi, A., Ghosh, A. K., Gkizas, S., Golchha, S. K., Goncharov, A., Gossl, M., Gotberg, M., Greco, F., Grundeken, M. J., Gupta, D., Gupta, S., Guray, U., Hahalis, G., Hakim Vista, J., Hamid, M. A., Hammoudeh, A., Hasan, A. R. I., Hatsumura, F. E., Heintzen, M. P., Helal, T., Hetherington, S., Hewarathna, U. I., Hioki, H., Hissein, F., Ho-Ping, Y., Homs, S., Huber, K., Ibarra, F. M., Ielasi, A., Ipek, E., Jambunathan, R., Jamshidi, P., Jarrad, I., Javier, W., Jensen, J., Jimenez-Quevedo, P., Kalpak, O., Kan, J., Kanaan, T., Kao, D. H. M., Karamfiloff, K., Karegren, A., Karjalainen, P. P., Kasabov, R., Katsimagklis, G. D., Kaul, U., Khan, A., Kiemeneij, E., Kiviniemi, T., Kleiban, A., Komiyama, N., Konteva, M., Koshy, G., Krepsky, A. M., Kuljit, S., Kulkarni, P., Kumar, V., Kuznetsov, I., Lai, G., Lateef, M. A., Lawand, S., Le Hong, T., Lettieri, C., Levy, G., Lindvall, P., Maitra, A., Makowski, M., Mamas, M. A., Mandal, S. C., Mangalanandan, P., Marin, R., Mashhadi, M., Matsukage, T., Meier, B., Milosavljevic, B., Miro, S. S., Mitov, A., Moeriel, M., Moguel, R., Mohanty, A., Montalescot, G., Morsdorf, W., Moscato, F., Muniz, A., Muraglia, S., Myc, J., Nada, A., Nair, P., Namazi, M. H., Naraghipour, F., Nguyen, Q. N., Nicosia, A., Nikas, D., Ober, M., Ocaranza-Sanchez, R., Olivecrona, G., Pahlajani, D., Pandey, B. P., Parma, A., Parma, R., Patsilinakos, S. P., Pattam, J., Peddi, S., Perez, P. R., Peruga, J. Z., Pescoller, F., Petrov, I., Piatti, L., Pico-Aracil, F., Pina, J., Piroth, Z., Popa, V., Pourbehi, M. R., Pradhan, A. K., Prida, X. E., Purohit, B. V., Pyun, W. B., Quang Hung, D., Rada, I., Rafizadeh, O., Rahman, M. A., Rai, L., Ramsewak, A., Ravindran, R., Rodriguez De Leiras, O. S., Rodriguez Esteban, M., Roque Figueira, H., Saket, A., Sakhov, O., Saktheeswaran, M. K., Salachas, A., Sallam, A., Sampaolesi, A., Samy, A., Sanchis, J., Santaera, O., Santarelli, A., Santharaj, W. S., Sarango, B., Satheesh, S., Schmitz, T., Schuhlen, H., Seewoosagur, R., Segev, A., Seisembekov, V., Semitko, S., Sengottuvelu, G., Sepulveda Varela, P., Sethi, A., Sharma, A., Sharma, R. K., Shi, Hy., Simsek, M. A., Siqueira, B., Skalidis, E., Slawin, J., Sorokhtey, L., Spaulding, C., Srinivas, B., Srinivasan, M., Stakos, D., Stojkovic, S., Tacoy, G., Tawade, M., Tiecco, F., Tondi, S., Torresani, E. M., Tousek, P., Tran, T., Trantalis, G., Triantafyllou, K., Trivedi, R., Trivisonno, A., Tsui, K. L., Turkoglu, C., Tzung-Dau, W., Ueno, H., Urban, U., Uretsky, B. F., Uscumlic, A., Venugopal, V., Verney, R., Vilar, J. V., Villacorta, V. G., Vishwanath, R., Vlachojannis, G. J., Vlachojannis, M., Vlad, V., Von Birgelen, C., Vukcevic, V., Wahab, A., Waksman, R., Wei-Wen, L., Weisz, G., Whittaker, A., Yadav, A., Yokoi, Y., Zacharoulis, A., Zahran, M., Zamani, J., Ziakas, A., Zimmermann, J. P., and Cardiology

Subjects
Hirudin, Percutaneous, Antithrombin, medicine.medical_treatment, Psychological intervention, 030204 cardiovascular system & hematology, medical, 0302 clinical medicine, Peptide Fragment, Surveys and Questionnaires, Surveys and Questionnaire, Medicine, Bivalirudin, 030212 general & internal medicine, Societies, Medical, Transradial, Anticoagulant, Hirudins, Middle Aged, Recombinant Protein, Recombinant Proteins, Femoral Artery, Radial Artery, Cardiology, acute coronary syndrome, bivalirudin, transradial, adult, antithrombins, cardiology, femoral artery, hirudins, humans, middle aged, peptide fragments, percutaneous coronary intervention, recombinant proteins, societies, medical, surveys and questionnaires, attitude of health personnel, radial artery, Acute coronary syndrome, Cardiology and Cardiovascular Medicine, Human, medicine.drug, Adult, medicine.medical_specialty, Attitude of Health Personnel, medicine.drug_class, MEDLINE, Antithrombins, 03 medical and health sciences, societies, Percutaneous Coronary Intervention, Internal medicine, Humans, Acute Coronary Syndrome, Peptide Fragments, Management of acute coronary syndrome, business.industry, Percutaneous coronary intervention, medicine.disease, business
Abstract

AIMS Our aim was to report on a survey initiated by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) collecting the opinion of the cardiology community on the invasive management of acute coronary syndrome (ACS), before and after the MATRIX trial presentation at the American College of Cardiology (ACC) 2015 Scientific Sessions. METHODS AND RESULTS A web-based survey was distributed to all individuals registered on the EuroIntervention mailing list (n=15,200). A total of 572 and 763 physicians responded to the pre- and post-ACC survey, respectively. The radial approach emerged as the preferable access site for ACS patients undergoing invasive management with roughly every other responder interpreting the evidence for mortality benefit as definitive and calling for a guidelines upgrade to class I. The most frequently preferred anticoagulant in ACS patients remains unfractionated heparin (UFH), due to higher costs and greater perceived thrombotic risks associated with bivalirudin. However, more than a quarter of participants declared the use of bivalirudin would increase after MATRIX. CONCLUSIONS The MATRIX trial reinforced the evidence for a causal association between bleeding and mortality and triggered consensus on the superiority of the radial versus femoral approach. The belief that bivalirudin mitigates bleeding risk is common, but UFH still remains the preferred anticoagulant based on lower costs and thrombotic risks.

Published
2016

9. P1751LATIN - A template for effective AMI management in developing countries

Author

Mehta, S, primary, Botelho, R, additional, Fernandez, F, additional, Feres, F, additional, Abizaid, A, additional, Cade, J, additional, Perin, M, additional, Prudente, M, additional, Calvanti, R, additional, Dusilek, C, additional, Matheus, C, additional, Ceschim, M, additional, Vieira, D, additional, Torres, M A, additional, and Mazzini, J, additional

Published
2019
Full Text
View/download PDF

10. P3352Telemedicine transcends national boundaries in quest of creating a behemoth ami program

Author

Mehta, S, primary, Botelho, R, additional, Fernandez, F, additional, Feres, F, additional, Abizaid, A, additional, Cade, J, additional, Perin, M, additional, Prudente, M, additional, Cavalcanti, R, additional, Dusilek, C, additional, Frauenfelder, A, additional, Matheus, C, additional, Pinto, G, additional, Mazzini, J, additional, and Quintero, S, additional

Published
2019
Full Text
View/download PDF

11. P5241Balancing limited resources, infra-structure deficits & cultural differences in sustaining the growth of LATIN telemedicine program

Author

Mehta, S, primary, Botelho, R, additional, Fernandez, F, additional, Feres, F, additional, Abizaid, A, additional, Cade, J, additional, Perin, M, additional, Prudente, M, additional, Cavalcanti, R, additional, Dusilek, C, additional, Nola, F, additional, Pisana, L, additional, Safie, R, additional, Aboushi, H, additional, and Lopez, C, additional

Published
2019
Full Text
View/download PDF

12. P575Merging technologies to provide Mexico an innovative nationwide AMI management network

Author

Mehta, S, primary, Botelho, R, additional, Fernandez, F, additional, Alcocer Gamba, M, additional, De Los Rios, O, additional, Ricalde, A, additional, Acosta, H, additional, Villagra, L, additional, Perin, M, additional, Feres, F, additional, Frauenfelder, A, additional, Matheus, C, additional, Ceschim, M, additional, Pinto, G, additional, and Mazzini, J, additional

Published
2019
Full Text
View/download PDF

14. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials

Author

Costa, F., Klaveren, D. van, James, S., Heg, D., Raber, L., Feres, F., Pilgrim, T., Hong, M.K., Kim, H.S., Colombo, A., Steg, P.G., Zanchin, T., Palmerini, T., Wallentin, L., Bhatt, D.L., Stone, G.W., Windecker, S., Steyerberg, E.W., Valgimigli, M., and PRECISE-DAPT Study Investigators

Subjects
610 Medicine & health, 360 Social problems & social services
Abstract

BACKGROUND Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischaemic events after coronary stenting, but increases bleeding. Guidelines support weighting bleeding risk before the selection of treatment duration, but no standardised tool exists for this purpose. METHODS A total of 14 963 patients treated with DAPT after coronary stenting-largely consisting of aspirin and clopidogrel and without indication to oral anticoagulation-were pooled at a single-patient level from eight multicentre randomised clinical trials with independent adjudication of events. Using Cox proportional hazards regression, we identified predictors of out-of-hospital Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding stratified by trial, and developed a numerical bleeding risk score. The predictive performance of the novel score was assessed in the derivation cohort and validated in patients treated with percutaneous coronary intervention from the PLATelet inhibition and patient Outcomes (PLATO) trial (n=8595) and BernPCI registry (n=6172). The novel score was assessed within patients randomised to different DAPT durations (n=10 081) to identify the effect on bleeding and ischaemia of a long (12-24 months) or short (3-6 months) treatment in relation to baseline bleeding risk. FINDINGS The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, white-blood-cell count, and previous spontaneous bleeding) showed a c-index for out-of-hospital TIMI major or minor bleeding of 0·73 (95% CI 0·61-0·85) in the derivation cohort, and 0·70 (0·65-0·74) in the PLATO trial validation cohort and 0·66 (0·61-0·71) in the BernPCI registry validation cohort. A longer DAPT duration significantly increased bleeding in patients at high risk (score ≥25), but not in those with lower risk profiles (pinteraction=0·007), and exerted a significant ischaemic benefit only in this latter group. INTERPRETATION The PRECISE-DAPT score is a simple five-item risk score, which provides a standardised tool for the prediction of out-of-hospital bleeding during DAPT. In the context of a comprehensive clinical evaluation process, this tool can support clinical decision making for treatment duration. FUNDING None.

Published
2017

15. GUIDELINES FOR THE BRAZILIAN SOCIETY OF CARDIOLOGY ON PROFESSIONAL AND INSTITUTIONAL QUALITY, CENTER FOR PROFESSIONAL TRAINING AND CERTIFICATION IN HEMODYNAMICS AND INTERVENTIONAL CARDIOLOGY

Author

Feres, F., Costa, R. A., Siqueira, D., Costa Jr, J. R., Chamie, D., Staico, R., Chaves, A. J., Abizaid, A., Marin-Neto, J. A. |Rassi Jr, A., Botelho, R., Alves, C. M. R. [UNIFESP], Saad, J. A., Mangione, J. A., Lemos, P. A., Quadros, A. S., Queiroga, M. A. C., Cantarelli, M. J. C., and Figueira, H. R.

Abstract

Inst Dante Pazzanese Cardiol, Sao Paulo, SP, Brazil Univ Sao Paulo, Fac Med, Hosp Clin, Ribeirao Preto, SP, Brazil Hosp Coracao Anis Rassi, Goiania, Go, Brazil Inst Coracao Triangulo, Uberlandia, MG, Brazil Escola Paulista Med, Sao Paulo, SP, Brazil Hosp Felicio Rocho, Belo Horizonte, MG, Brazil Real & Benemerita Soc Portuguesa Beneficencia, Sao Paulo, SP, Brazil Univ Sao Paulo, Fac Med, Inst Coracao, Hosp Clin, Sao Paulo, SP, Brazil Fundacao Univ Cardiol, Inst Cardiol Rio Grande do Sul, Porto Alegre, RS, Brazil Hosp Santa Paula, Cardioctr, Joao Pessoa, Paraiba, Brazil Hosp Bandeirantes, Sao Paulo, SP, Brazil Clin Sao Vicente, Rio De Janeiro, RJ, Brazil Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil Web of Science

Published
2017

16. P6033Development of immediate and late predictor score of success after percutaneous mitral valvoplasty in patients with mitral stenosis

Author

Bustamante Prota Filho, L E, primary, Cezar Viana Queiroz, C, additional, Costa Wohnrath, F, additional, Amaral Carvalho Carboni, F, additional, Reis Cunha Da Costa, G, additional, Ileana Panchano Castro, J, additional, Sousa Da Silva, W, additional, Meneguz Moreno, R, additional, Ribamar Costa Junior, J, additional, Antonio Cunha Abizaid, A, additional, and Feres, F, additional

Published
2018
Full Text
View/download PDF

17. P4588Echo guided septal radiofrequency ablation for treatment of obstructive hypertrophic cardiomiopathy - Case series

Author

Valdigem, B P, primary, Correa, E B, additional, Moreira, D A R, additional, Andalaft, R B, additional, Masciarelli Pinto, I B, additional, Abizaid, A A C, additional, Cano, M N, additional, Armaganijan, L V, additional, Paladino Filho, T A, additional, Verissimo, O, additional, Lebihan, D, additional, Feres, F, additional, Viesi, J H Z, additional, Nigro Neto, C, additional, and Barreto, R B M, additional

Published
2018
Full Text
View/download PDF

18. P3179Exploring the value of the PRECISE-DAPT score after complex percutaneous coronary intervention to inform dual antiplatelet therapy duration decision-making

Author

Costa, F, primary, Van Klaveren, D, additional, Feres, F, additional, Raber, L, additional, Pilgrim, T, additional, Hong, M K, additional, Kim, H S, additional, Colombo, A, additional, Steg, P G, additional, Stone, G W, additional, Bhatt, D L, additional, Windecker, S, additional, Steyerberg, E, additional, and Valgimigli, M, additional

Published
2018
Full Text
View/download PDF

19. P4491Telemedicine-guided STEMI networks - Pragmatic and cost-effective strategies for population-based AMI care in developing countries

Author

Mehta, S, primary, Rodriguez, D, additional, Botelho, R, additional, Fernandez, F, additional, Dusilek, C, additional, Cardoso, R, additional, Lacativa, M, additional, Perin, M, additional, Feres, F, additional, Abizaid, A, additional, Campos, C, additional, Vega, R, additional, Bojanini, F, additional, Alcocer, M, additional, and Estrada, A, additional

Published
2018
Full Text
View/download PDF

20. DIRETRIZ DA SOCIEDADE BRASILEIRA DE CARDIOLOGIA E DA SOCIEDADE BRASILEIRA DE HEMODINÂMICA E CARDIOLOGIA INTERVENCIONISTA SOBRE INTERVENÇÃO CORONÁRIA PERCUTÂNEA

Author

Feres, F, primary, Costa, RA, additional, Siqueira, D, additional, Costa Jr, JR, additional, Chamié, D, additional, Staico, R, additional, Chaves, AJ, additional, Abizaid, A, additional, Marin-Neto, JA, additional, Rassi Jr, A, additional, Botelho, R, additional, Alves, CMR, additional, Saad, JA, additional, Mangione, JA, additional, Lemos, PA, additional, Quadros, AS, additional, Queiroga, MAC, additional, Cantarelli, MJC, additional, and Figueira, HR, additional

Published
2017
Full Text
View/download PDF

22. Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: Results from the E-Five Registry.

Author

Sinha N., Rothman M.T., Jain A.K., Meredith I.T., Lotan C., Feres F., Zambahari R., Sinha N., Rothman M.T., Jain A.K., Meredith I.T., Lotan C., Feres F., and Zambahari R.

Abstract

Objective: To retrospectively evaluate the 12-month effectiveness of the Endeavor zotarolimus-eluting stent (ZES) in diabetic versus non-diabetic patients enrolled in the E-Five Registry. Design and Setting: The E-Five Registry is a prospective, multicentre registry of 8314 patients presenting with symptomatic coronary artery disease treated with the Endeavor (ZES). Patients were treated at 188 centres located in 37 countries across Europe, Latin America and Asia Pacific. Patient(s): There were 2721 (32.7%) patients with diabetes (DM) and among these patients 682 were insulin-treated (ITDM) and 2039 were non-insulin-treated diabetic patients (NITDM). Intervention(s): All enrolled patients received an Endeavor ZES and were followed for 12 months. Main outcome measurements: The primary outcome measure was major adverse cardiac event (MACE) at 12 months. Secondary endpoints included target lesion revascularisation (TLR), target vessel revascularisation (TVR), target vessel failure (TVF) and stent thrombosis. Result(s): Compared with non-DM patients, DM patients had higher rates of MACE (9.7% vs 6.4%, p<0.001), TLR (5.3% vs 4.0%, p=0.028) and Academic Research Consortium (ARC) definite and probable stent thrombosis (1.5% vs 0.9%, p=0.041). Compared with non-DM patients, ITDM patients had higher rates of MACE (12.6% vs 6.4%, p<0.001). ITDM patients had higher rates of death (6.7% vs 1.7%, p<0.001), cardiac death (4.5% vs 1.2%, p<0.001) and TLR (6.5% vs 4.0%, p=0.011) than non-DM patients. Conclusion(s): The Endeavor ZES performed well in DM patients; however, DM patients experienced higher rates of adverse clinical events compared with non-DM patients. Trial Reg No: Clinical trial registration information: http://www.clinicaltrials.gov; Unique identifier: NTC00623441.

Published
2012

23. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries

Author

Sousa, J.E. (Eduardo), Jaeger, J. (Judith), Popma, J.J. (Jeffrey), Costa, M.A. (Marco), Sousa, A.G.M.R. (Amanda), Abizaid, A.C. (Alexandre), Seixas, A.C. (Ana), Abizaid, A.S. (Andrea), Feres, F. (Fausto), Mattos, L.A. (Luiz), Falotico, R. (Robert), Serruys, P.W.J.C. (Patrick), Sousa, J.E. (Eduardo), Jaeger, J. (Judith), Popma, J.J. (Jeffrey), Costa, M.A. (Marco), Sousa, A.G.M.R. (Amanda), Abizaid, A.C. (Alexandre), Seixas, A.C. (Ana), Abizaid, A.S. (Andrea), Feres, F. (Fausto), Mattos, L.A. (Luiz), Falotico, R. (Robert), and Serruys, P.W.J.C. (Patrick)

Abstract

BACKGROUND: The safety and efficacy of sirolimus-eluting stenting have been demonstrated, but the outcome of patients treated with this novel technology beyond the first year remains unknown. We sought to evaluate the angiographic, intravascular ultrasound (IVUS), and clinical outcomes of patients treated with sirolimus-eluting stents 2 years after implantation. METHODS AND RESULTS: This study included 30 patients treated with sirolimus-eluting Bx Velocity stenting (slow release [SR], n=15, and fast release [FR], n=15) in Sao Paulo, Brazil. Twenty-eight patients underwent 2-year angiographic and IVUS follow-up. No deaths occurred during the study period. In-stent late loss was slightly greater in the FR group (0.28+/-0.4 mm) than in the SR group (-0.09+/-0.23 mm, P=0.007). No patient had in-stent restenosis. At 2-year follow-up, only 1 patient (FR group) had a 52% diameter stenosis within the lesion segment, which required repeat revascularization. The target-vessel revascularization rate for the entire cohort was 10% (3/30) at 2 years. All other patients had < or =35% diameter stenosis. Angiographic lumen loss at the stent edges was also minimal (in-lesion late loss was 0.33+/-0.42 mm [FR] and 0.13+/-0.29 mm [SR]). In-stent neointimal hyperplasia volume, as detected by IVUS, remained minimal after 2 years (FR= 9.90+/-9 mm3 and SR=10.35+/-9.3 mm3). CONCLUSIONS: This study demonstrates the safety and efficacy of sirolimus-eluting Bx Velocity stents 2 years after implantation in humans. In-stent lumen dimensions remained essentially unchanged at 2-year follow-up in the 2 groups, although angiographic lumen loss was slightly higher in the FR group. Restenosis "catch-up" was not found in our patient population.

Published
2003

24. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study

Author

Sousa, J.E. (Eduardo), Feres, F. (Fausto), Mattos, L.A. (Luiz), Centemero, M., Maldonado, G., Abizaid, A.S. (Andrea), Popma, J.J. (Jeffrey), Pinto, I.M.F. (Ibraim), Jaeger, J. (Judith), Falotico, R. (Robert), Costa, M.A. (Marco), Sousa, A.G.M.R. (Amanda), Serruys, P.W.J.C. (Patrick), Abizaid, A.C. (Alexandre), Sousa, J.E. (Eduardo), Feres, F. (Fausto), Mattos, L.A. (Luiz), Centemero, M., Maldonado, G., Abizaid, A.S. (Andrea), Popma, J.J. (Jeffrey), Pinto, I.M.F. (Ibraim), Jaeger, J. (Judith), Falotico, R. (Robert), Costa, M.A. (Marco), Sousa, A.G.M.R. (Amanda), Serruys, P.W.J.C. (Patrick), and Abizaid, A.C. (Alexandre)

Abstract

BACKGROUND: We have previously reported the safety and effectiveness of sirolimus-eluting stents for the treatment of de novo coronary lesions. The present investigation explored the potential of this technology to treat in-stent restenosis. METHODS AND RESULTS: Twenty-five patients with in-stent restenosis were successfully treated with the implantation of 1 or 2 sirolimus-eluting Bx VELOCITY stents in Sao Paulo, Brazil. Nine patients received 2 stents (1.4 stents per lesion). Angiographic and volumetric intravascular ultrasound (IVUS) images were obtained after the procedure and at 4 and 12 months. All vessels were patent at the time of 12-month angiography. Angiographic late loss averaged 0.07+/-0.2 mm in-stent and -0.05+/-0.3 mm in-lesion at 4 months, and 0.36+/-0.46 mm in-stent and 0.16+/-0.42 mm in-lesion after 12 months. No patient had in-stent or stent margin restenosis at 4 months, and only one patient developed in-stent restenosis at 1-year follow-up. Intimal hyperplasia by 3-dimensional IVUS was 0.92+/-1.9 mm(3) at 4 months and 2.55+/-4.9 mm(3) after 1 year. Percent volume obstruction was 0.81+/-1.7% and 1.76+/-3.4% at the 4- and 12-month follow-up, respectively. There was no evidence of stent malapposition either acutely or in the follow-up IVUS images, and there were no deaths, stent thromboses, or repeat revascularizations. CONCLUSION: This study demonstrates the safety and the potential utility of sirolimus-eluting Bx VELOCITY stents for the treatment of in-stent restenosis.

Published
2003

25. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study

Author

Sousa, JE, Costa, M (Marco), Abizaid, A, Sousa, AGMR, Feres, F, Mattos, LA, Centemero, M, Maldonado, M, Abizaid, AS, Pinto, IMF, Falotico, R, Jaeger, J, Popma, JJ, Serruys, PWJC (Patrick), Sousa, JE, Costa, M (Marco), Abizaid, A, Sousa, AGMR, Feres, F, Mattos, LA, Centemero, M, Maldonado, M, Abizaid, AS, Pinto, IMF, Falotico, R, Jaeger, J, Popma, JJ, and Serruys, PWJC (Patrick)

Published
2003

27. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study

Author

Sousa, J.E. (Eduardo), Feres, F. (Fausto), Pinto, I.M.F. (Ibraim), Seixas, A.C. (Ana), Staico, R., Mattos, L.A. (Luiz), Popma, J.J. (Jeffrey), Sousa, A.G.M.R. (Amanda), Jaeger, J. (Judith), Falotico, R. (Robert), Costa, M.A. (Marco), Abizaid, A.S. (Andrea), Serruys, P.W.J.C. (Patrick), Abizaid, A.C. (Alexandre), Sousa, J.E. (Eduardo), Feres, F. (Fausto), Pinto, I.M.F. (Ibraim), Seixas, A.C. (Ana), Staico, R., Mattos, L.A. (Luiz), Popma, J.J. (Jeffrey), Sousa, A.G.M.R. (Amanda), Jaeger, J. (Judith), Falotico, R. (Robert), Costa, M.A. (Marco), Abizaid, A.S. (Andrea), Serruys, P.W.J.C. (Patrick), and Abizaid, A.C. (Alexandre)

Abstract

BACKGROUND: Restenosis remains an important limitation of interventional cardiology. Therefore, we aimed to determine the safety and efficacy of sirolimus (a cell-cycle inhibitor)-coated BX Velocity stents. METHODS AND RESULTS: Thirty patients with angina pectoris were electively treated with 2 different formulations of sirolimus-coated stents (slow release [SR], n=15, and fast release [FR], n=15). All stents were successfully delivered, and patients were discharged without clinical complications. Independent core laboratories analyzed angiographic and 3D volumetric intravascular ultrasound data (immediately after procedure and at 4-month follow-up). Eight-month clinical follow-up was obtained for all patients. There was minimal neointimal hyperplasia in both groups (11.0+/-3.0% in the SR group and 10.4+/-3.0% in the FR group, P:=NS) by ultrasound and quantitative coronary angiography (in-stent late loss, 0.09+/-0.3 mm [SR] and -0.02+/-0.3 mm [FR]; in-lesion late loss, 0.16+/-0.3 mm [SR] and -0.1+/-0.3 mm [FR]). No in-stent or edge restenosis (diameter stenosis >or=50%) was observed. No major clinical events (stent thrombosis, repeat revascularization, myocardial infarction, or death) had occurred by 8 months. CONCLUSIONS: The implantation of sirolimus-coated BX Velocity stents is feasible and safe and elicits minimal neointimal proliferation. Additional placebo-controlled trials are required to confirm these promising results.

Published
2001

28. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries : A quantitative coronary angiography and three-dimensional intravascular ultrasound study

Author

Sousa, JE, Costa, M (Marco), Abizaid, A, Abizaid, AS, Feres, F, Pinto, IMF, Seixas, AC, Staico, R, Mattos, LA, Sousa, AGMR, Falotico, R, Jaeger, J, Popma, JJ, Serruys, PWJC (Patrick), Sousa, JE, Costa, M (Marco), Abizaid, A, Abizaid, AS, Feres, F, Pinto, IMF, Seixas, AC, Staico, R, Mattos, LA, Sousa, AGMR, Falotico, R, Jaeger, J, Popma, JJ, and Serruys, PWJC (Patrick)

Published
2001

30. Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation.

Author

Chamié D, Abizaid A, Costa JR Jr, Feres F, Almiro da Silva JF, Mattos LA, Staico R, Costa RA, Tanajura LF, Sousa AG, Sousa JE, Chamié, Daniel, Abizaid, Alexandre, Costa, J Ribamar Jr, Feres, Fausto, Almiro da Silva, J Fábio, Mattos, Luiz Alberto P, Staico, Rodolfo, Costa, Ricardo A, and Abizaid, Andréa

Abstract

Despite the expressive reduction in the intimal hyperplasia (IH) formation after DES implantation at the mid-term, late restenosis has been recently noticed. Our objective was to determine, by means of serial angiography (QCA) and intravascular ultrasound (IVUS) at two different time points, whether the occurrence of the "late catch-up" phenomenon occurs after sirolimus-eluting stent (SES) implantation. Thirty-eight non-complex patients treated with a single 18-mm SES who had systematic serial QCA and IVUS analyses at mean 8 and 20 months were enrolled. Primary endpoint is to evaluate the temporal course of IH formation after SES implantation, by comparing QCA in-stent late loss and IVUS percent IH obstruction between the invasive follow-ups. Mean cohort age was 59.3 years and 31.6% were diabetics. Baseline reference vessel diameter was 2.8 ± 0.4 mm and lesion length was 11.5 ± 3.5 mm. Left anterior descending artery was the most frequent target vessel (55.3%). Between 8 and 20 months, a non-significant increase in in-stent late loss from 0.10 ± 0.18 to 0.15 ± 0.30 mm (P = 0.38) was observed. By IVUS, a slight increase in the percent IH obstruction (1.03 ± 2.13 to 1.76 ± 1.87%, P = 0.12) was detected between the two evaluations. Interestingly, all the neoformed tissue accrued from 8 to 20 months accumulated in the distal portion of the stent. In the non-complex scenario, SES implantation was associated with a minimal, non-significant increase in the IH volume between 8 and 20 months. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

32. Correlation between quantitative angiographic and intravascular ultrasound parameters in patients treated with sirolimus analogous-eluting stents.

Author

Lasave LI, Costa JR Jr, Costa R, Abizaid A, Feres F, Staico R, Maldonado G, Mattos LA, Beraldo P, Sousa AG, Sousa JE, Lasave, Leandro Ignacio, Costa, J Ribamar Jr, Costa, Ricardo, Abizaid, Andrea, Feres, Fausto, Staico, Rodolfo, Maldonado, Galo, Mattos, Luiz A, and Beraldo, Pedro

Abstract

Despite the undeniable contribution of intravascular ultrasound (IVUS) and quantitative coronary angiography (QCA) to assess drug-eluting stent (DES) effectiveness, the way these image modalities correlate to each other and to target-lesion revascularization (TLR) after PCI, is yet to be established. Thus we sought to evaluate whether there is an acceptable correlation between QCA and IVUS after DES implantation. We analyzed 204 pts treated with DES: Zotarolimus- (126), Sirolimus- (57), and Biolimus (31) with baseline and follow-up QCA and IVUS. The correlation between QCA lumen loss (LL) and intimal hyperplasia (IH) volume obstruction by IVUS was assessed by multiple regression analysis. Two QCA parameters (in-segment diameter stenosis and in-segment LL) and one IVUS variable (in-stent volume of IH) were evaluated as quantitative surrogates of 6 month TLR. The receiver operating characteristic method with c-statistics was used to assess the ability of each surrogate endpoint to predict TLR. QCA LL correlated positively with IVUS IH volume of obstruction (r = 0.69; CI95% 0.61-0.75: P < 0.0001), independent of DES type. The 2 QCA parameters were superior to the IVUS parameter as surrogates for TLR. Of note, QCA LL (c = 0.99) correlated best with TLR, even better than percent DS. In the DES era there is a good correlation between QCA measured LL and IVUS IH volume and therefore can be used as a surrogate of DES efficacy. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

39. Safety and efficacy of a novel stent system with a protection net to prevent distal embolization: Preliminary results of the INSPIRE trial,Segurança e eficácia de um novo sistema de stent com rede de proteção para prevenção de embolização distal: Resultados preliminares do estudo INSPIRE

Author

Maia, F., Costa Jr, J. R., Costa, R. A., Staico, R., Feres, F., Vinicius Esteves, Tanajura, L. F., Chaves, Á J., Centemero, M., Mendes Jr, A., Brito, A. L., Abizaid, A., Maldonado, G., Siqueira, D., Mattos, L. A., Seixas, A. C., Sousa, A. G. M. R., and Sousa, J. E.

42. Late clinical outcomes of firebird™ sirolimus-eluting stent for the treatment of coronary artery disease in the daily practice 24-month follow-up of the CLARIFIRE registry,Resultados clínicos tardios do stent farmacológico liberador de sirolimus firebird® no tratamento de pacientes com doença arterial coronária na prática diária – seguimento de 24 meses do registro CLARIFIRE

Author

Souza, R., Costa, R. A., Abizaid, A., Buchalla, M., Bueno, R. R. L., Ximenes Meireles, G. C., Kleber Martins, Mont’alverne Filho, J. R., Costantini, C., Salvadori, D., Pimentel Filho, W. A., Abizaid, A. S., Castro, J. P., Ribeiro, E., and Feres, F.

43. Managing chronic coronary artery stable angina,Diretrizes de doença coronariana crônica angina estável

Author

Machado César, L. A., Pádua Mansur, A., Armaganijan, D., Amino, J. G., Sousa, A. C., Simão, A. F., Xavier Brito, A., Caramelli, B., Brito Vianna, C., Carlos Alberto Pastore, Rochitte, C. E., Cardoso Oliveira, C., Meneghetti, C., Calderaro, D., Campos Albuquerque, D., Stefanini, E., Martinez Filho, E. E., Feres, F., Rocha Dohmann, H. F., Pierri, H., Schneider, J. C., Ribeiro Cade, J., Tsutsui, J. M., Monteiro Ferreira, J. F., Torres, K., Atanes, L., Dallan, L. A., Simão, L. F., Goldwak, L. H., Moretti, M. A., Coelho, O. R., Ferreira Albuquerque, P., Puech Leão, P., Santos, R. D., Marino, R. L., Meneghello, R., Almeida Oliveira, S., Montenegro, S., Vaz, V. D., Hueb, W. A., Mathias Jr, W., and Ilha Guimarães, J.

45. Use of supralimusTMdrug eluting stent with sirolimus and absorbable polymer in the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention,Emprego do stent farmacológico supralimus™, com sirolimus e polímero absorvível, no tratamento de pacientes com síndrome coronária aguda submetidos a intervenção coronária percutânea

Author

Costa Jr, J. R., Abizaid, A., Arruda, J. A., Brito Jr, F. S., Feres, F., Costa, R. A., Costantini, C., Prudente, M. L., and Expedito da Silva

48. Diferentes doses de ciclofosfamida no sistema imune de ovinos

Author

Garcia Maurício, Chate Sabrina Caruso, Porto Ana Carolina Rusca, Figueira Yara Ferreira, Diegues André Dias, Feres Flávia Corbari, and Martins Maria de Fátima

Subjects
ciclofosfamida, imunossupressão, ovinos, Agriculture, Agriculture (General), S1-972
Abstract

O objetivo deste trabalho foi avaliar o efeito de diferentes doses de ciclofosfamida como indutor de imunossupressão experimental em ovinos. Foram empregados 30 animais, divididos em quatro grupos experimentais. Os animais dos grupos I, II e III foram submetidos, respectivamente, às doses de 10, 25 e 40mg kg-1 e os do grupo IV não receberam a droga, permanecendo como controle. Todos os animais foram imunizados com vacina contra a brucelose e, seis dias após a vacinação, foi feita a titulação através da soroaglutinação rápida em placa. Foi feita também a contagem de linfócitos sangüíneos e a dosagem de gamaglobulinas séricas, diariamente, durante uma semana, após a aplicação da ciclofosfamida. Houve óbitos apenas em alguns animais do grupo III (40mg kg-1). Assim, a droga mostrou-se segura com doses inferiores a 25mg kg-1. Quanto à imunossupressão, a mesma pôde ser demonstrada tanto nos animais que receberam 25mg kg-1, quanto aqueles que receberam 40mg/kg, através da análise dos resultados das contagens de linfócitos e dos títulos pós-vacinais anti-brucela. A dose de 25mg kg-1 de ciclofosfamida mostrou-se, assim, a mais adequada para ser usada em modelos de imunodepressão em ovinos, considerando sua ação imunossupressora e sua segurança e toxicidade.

Published
2004

49. Arteriografia coronária com cateter de muito baixo perfil. Eficácia e segurança do procedimento e da alta hospitalar aos 60 minutos

Author

Berti Sergio, Feres Fausto, Castro Danilo, Gusmão Marcos, Staico Rodolfo, Padilha Rone, Chaves Aurea, Centemero Marinella, Mattos Luiz A., Sousa Amanda, and Sousa J. Eduardo

Subjects
cateterismo cardíaco, angiografia coronária, deambulação precoce, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

OBJETIVO: Avaliar a eficiência, a segurança e a praticidade da angiografia coronária com cateteres 4 French (F), pela técnica de Judkins. MÉTODOS: De agosto/95 a janeiro/96, 70 pacientes com suspeita de insuficiência coronária submeteram-se à cinecoronariografia , utilizando introdutores e cateteres 4F. Após o exame, realizava-se compressão local por 15min e, 60min após, os pacientes eram orientados a caminhar, sob vigilância , sendo dada a alta hospitalar após 4h, . RESULTADOS: A idade variou de 31 a 83 (m = 57) anos, sendo 39 (56%) homens, com peso entre 43 a 101 (m = 69) kg. Obteve-se ótima qualidade de imagem em 62 casos (88%), havendo a necessidade de substituição por cateteres de maior calibre (6 a 8F) em 8 (12%) pacientes. Não ocorreram complicações vasculares ou sangramentos maiores. Em apenas 2 (3%) casos, houve discreto sangramento, resolvido com nova compressão local. Sessenta pacientes (85%) deambularam aos 60±5min e tiveram alta hospitalar com 4h, em média. CONCLUSÃO: A utilização de cateteres 4F por via femoral, para realização de cinecoronariografia permite a deambulação muito precoce (média = 60±5min) e sem complicações hemorrágicas. Verificaram-se pequena utilização de contraste (média = 60ml) e redução da permanência hospitalar. Esta técnica torna o exame cinecoronariográfico mais simples, menos traumático e menos invasivo.

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results